Argos Therapeutics (ARGS) Misses Q1 EPS by 1c

Argos Therapeutics (NASDAQ: ARGS) reported Q1 EPS of ($0.57), $0.01 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $146.4 thousand versus the consensus estimate of $180 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• Voya Financial warns shareholders about unsanctioned TCIM straw poll
• Darden Restaurants (DRI) Reports In-Line Q1 EPS, Misses on Revenue; Offers FY27 EPS Guidance